CIK 0001850266
AKLI Akili, Inc.
Insider trading from SEC Form 4. Last filing Jul 8, 2024.
In brief
Akili, Inc. (AKLI) has 28 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 8, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Akili, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
Every row filed, 46 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 2, 2024 | PureTech Health plc owner | UTender of shares Common Stockindirect: See footnote | -12,527,477 | - | - | 0 | Jul 8, 2024 |
| Jul 2, 2024 | Chamath Palihapitiya owner | UTender of shares Common Stockindirect: See Footnote | -8,100,000 | - | - | 0 | Jul 5, 2024 |
| Jul 2, 2024 | Temasek Holdings (Private) Ltd owner | UTender of shares Common Stock, par value $0.0001indirect: See Footnote | -10,336,425 | - | - | 0 | Jul 5, 2024 |
| Jul 2, 2024 | Chamath Palihapitiya owner | UTender of shares Common Stockindirect: See Footnote | -3,773,000 | - | - | 0 | Jul 5, 2024 |
| Jul 2, 2024 | Temasek Holdings (Private) Ltd owner | UTender of shares Earnout Sharesderivativeindirect: See Footnote | -1,172,697 | - | - | 0 | Jul 5, 2024 |
| Jul 2, 2024 | Chamath Palihapitiya owner | UTender of shares Common Stockindirect: See Footnote | -1,900,000 | - | - | 0 | Jul 5, 2024 |
| Jul 2, 2024 | Adam Gazzaley director | UTender of shares Common Stock, par value $0.0001 | -1,089,314 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | Matthew Franklin President & CEO | UTender of shares Common Stock, par value $0.0001 | -7,657 | - | - | 33,000 | Jul 2, 2024 |
| Jul 2, 2024 | Jacqueline Studer Chief Legal Officer | UTender of shares Common Stock, par value $0.0001 | -30,693 | - | - | 92,869 | Jul 2, 2024 |
| Jul 2, 2024 | Walter Edward Martucci II Chief Executive Officer | UTender of shares Common Stock, par value $0.0001 | -48,690 | - | - | 99,548 | Jul 2, 2024 |
| Jul 2, 2024 | John Spinale director | UTender of shares Common Stock, par value $0.0001indirect: By JAZZ Human Performance Opportunity Fund, L.P. | -693,226 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | Jacqueline Studer Chief Legal Officer | DDisposition to issuer Common Stock, par value $0.0001 | -92,869 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | Matthew Franklin President & CEO | DDisposition to issuer Common Stock, par value $0.0001 | -33,000 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | Walter Edward Martucci II Chief Executive Officer | DDisposition to issuer Common Stock, par value $0.0001 | -99,548 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | John Spinale director | UTender of shares Common Stock, par value $0.0001indirect: By JAZZ Human Performance Technology Fund, L.P. | -3,063,364 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | Jacqueline Studer Chief Legal Officer | DDisposition to issuer Stock Option (Right to buy)derivative | -280,500 | - | - | 0 | Jul 2, 2024 |
| Jul 2, 2024 | John Spinale director | DDisposition to issuer Stock Option (Right to Buy)derivative | -44,000 | - | - | 0 | Jul 2, 2024 |
| Jun 7, 2024 | Jacqueline Studer Chief Legal Officer | FTax withholding Common Stock | -5,118 | $0.42 | $2,163 | 408,212 | Jun 11, 2024 |
| May 2, 2024 | Walter Edward Martucci II Chief Executive Officer | FTax withholding Common Stock | -5,174 | $0.41 | $2,115 | 895,446 | May 6, 2024 |
| May 2, 2024 | Jacqueline Studer Chief Legal Officer | FTax withholding Common Stock | -1,840 | $0.41 | $752 | 413,330 | May 6, 2024 |
| Mar 10, 2024 | Matthew Franklin President & CEO | FTax withholding Common Stock | -1,615 | $0.34 | $549 | 752,283 | Mar 12, 2024 |
| Mar 10, 2024 | Walter Edward Martucci II Chief Executive Officer | FTax withholding Common Stock | -2,599 | $0.34 | $884 | 900,620 | Mar 12, 2024 |
| Mar 10, 2024 | Jacqueline Studer Chief Legal Officer | FTax withholding Common Stock | -1,032 | $0.34 | $351 | 415,170 | Mar 12, 2024 |
| Feb 22, 2024 | John Spinale director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Feb 23, 2024 |
| Dec 7, 2023 | Jacqueline Studer Chief Legal Officer | AGrant or award Common Stock | +69,750 | - | - | 416,202 | Dec 8, 2023 |
| Dec 7, 2023 | Santosh Shanbhag Chief Financial Officer | AGrant or award Common Stock | +69,750 | - | - | 392,417 | Dec 8, 2023 |
| Dec 7, 2023 | Santosh Shanbhag Chief Financial Officer | AGrant or award Stock Option (Right to buy)derivative | +280,500 | $0.00 | $0 | 280,500 | Dec 8, 2023 |
| Dec 7, 2023 | Jacqueline Studer Chief Legal Officer | AGrant or award Stock Option (Right to buy)derivative | +280,500 | $0.00 | $0 | 280,500 | Dec 8, 2023 |
| Nov 2, 2023 | Walter Edward Martucci II Chief Executive Officer | FTax withholding Common Stock | -5,337 | $0.39 | $2,091 | 903,219 | Nov 6, 2023 |
| Nov 2, 2023 | Jacqueline Studer Chief Legal Officer | FTax withholding Common Stock | -1,840 | $0.39 | $721 | 346,452 | Nov 6, 2023 |
| Nov 2, 2023 | Santosh Shanbhag Chief Financial Officer | FTax withholding Common Stock | -969 | $0.39 | $380 | 322,667 | Nov 6, 2023 |
| Oct 12, 2023 | Matthew Franklin President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +1,057,180 | $0.00 | $0 | 1,057,180 | Oct 13, 2023 |
| Nov 2, 2022 | Mary Hentges director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Nov 4, 2022 |
| Nov 2, 2022 | Matthew Franklin See Remarks | AGrant or award Common Stock | +711,626 | - | - | 711,626 | Nov 4, 2022 |
| Nov 2, 2022 | Walter Edward Martucci II Chief Executive Officer | AGrant or award Common Stock | +109,096 | - | - | 109,096 | Nov 4, 2022 |
| Nov 2, 2022 | William A Jones Jr director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Nov 4, 2022 |
| Nov 2, 2022 | Chamath Palihapitiya director, owner | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Nov 4, 2022 |
| Nov 2, 2022 | Jacqueline Studer Chief Legal Officer | AGrant or award Common Stock | +37,612 | - | - | 37,612 | Nov 4, 2022 |
| Nov 2, 2022 | Santosh Shanbhag Chief Financial Officer | AGrant or award Common Stock | +19,795 | - | - | 19,795 | Nov 4, 2022 |
| Nov 2, 2022 | Jacqueline Studer Chief Legal Officer | AGrant or award Common Stock | +284,650 | - | - | 322,262 | Nov 4, 2022 |
| Nov 2, 2022 | Santosh Shanbhag Chief Financial Officer | AGrant or award Common Stock | +284,650 | - | - | 304,445 | Nov 4, 2022 |
| Nov 2, 2022 | Walter Edward Martucci II Chief Executive Officer | AGrant or award Common Stock | +2,988,832 | - | - | 3,097,928 | Nov 4, 2022 |
| Nov 2, 2022 | Matthew Franklin See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +973,234 | $0.00 | $0 | 973,234 | Nov 4, 2022 |
| Nov 2, 2022 | Jacqueline Studer Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +152,729 | $0.00 | $0 | 152,729 | Nov 4, 2022 |
| Nov 2, 2022 | Santosh Shanbhag Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +80,381 | $0.00 | $0 | 80,381 | Nov 4, 2022 |
| Nov 2, 2022 | Walter Edward Martucci II Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +442,995 | $0.00 | $0 | 442,995 | Nov 4, 2022 |
Insiders
Everyone who has filed a Form 4 here.
- Matthew FranklinSee Remarks
- Adam Gazzaleydirector
- Mary Hentgesdirector
- William A Jones Jrdirector, officer
- Walter Edward Martucci IIChief Executive Officer
- Chamath Palihapitiyadirector, owner, other
- PureTech Health plcowner
- Santosh ShanbhagChief Financial Officer
- John Spinaledirector
- Jacqueline StuderChief Legal Officer
- Temasek Holdings (Private) Ltdowner
Questions about AKLI
Answered from the filings on this page, as of the latest one.
Are insiders buying AKLI?
No. In the last 90 days no insider at Akili, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AKLI on the open market?
No open-market trade has been scored at Akili, Inc.. The latest Form 4 on file was filed on Jul 8, 2024 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Akili, Inc.?
11 people have filed a Form 4 at Akili, Inc., among them Matthew Franklin (See Remarks), Adam Gazzaley (director), Mary Hentges (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.